Table 1

Major ongoing clinical trials of renal-sparing treatment strategies

Drug	Trial acronym	Phase	Sample size
Natriuretic peptides
Nesiritide	ASCEND-HF	IV	7000
CD-NP	CONDITION-HF	II	380
Vasopressin receptor antagonist
Tolvaptan	EVEREST	III	3600
Conivaptan	CONVERT-HF	III	105
Lixivaptan	BALANCE	III	650
Adenosine A₁ receptor antagonists
Rolofylline	PROTECT-1 & -2	III	2000
SLV320	RENO-DEFEND 1	II	500
BG-9928	POSEIDON/TRIDENT	II/III	300/900
Standard treatment
Loop diuretics	DOSE-AHF	IV	300
Ultrafiltration	CARRESS	IV	200